CD4+CD25+调节性T细胞、IL-2与免疫耐受

近年来,越来越多的研究表明CD4+CD25+调节性T细胞在免疫耐受的过程中起着非常重要的作用。IL-2作为一种T细胞生长因子调控着调节性T细胞诱导免疫耐受的过程。IL-2维持着中枢及外周的调节性T细胞的活性,但是对胸腺调节性T细胞的发育是非必要的。同时,IL-2信号影响着调节性T细胞的功能并维持着其的竞争适应性。因此,CD4+CD25+调节性T细胞通过与IL-2之间形成的免疫网络调控着免疫耐受的过程,从而影响着机体的免疫平衡。     

调节性T细胞与胶质瘤的免疫治疗

调节性T细胞（regulatory T cell,Treg）是一群具有抑制其它免疫细胞功能的起负性调控的细胞群. Treg细胞能抑制多种免疫细胞,如CD4+T和CD8+T淋巴细胞、NK细胞、B淋巴细胞以及树突状细胞的活化和增殖,是体内维持免疫系统稳定,防止出现自身免疫性疾病重要因素.最新研究表明,Treg细胞在肿瘤免疫逃逸中也发挥重要作用. 肿瘤细胞通过扩增或招募Treg细胞,抑制机体对肿瘤的免疫作用,由此可知,Treg细胞在肿瘤的发生和发展过程中发挥重要作用. 因此,抑制Treg细胞的活性和数量是包括胶质瘤在内的肿瘤免疫治疗有效的方式.     

1型调节性T细胞的表型和功能

1型调节性T细胞(Tr1)在免疫耐受的诱导和维持过程中发挥重要作用。Tr1细胞通常在免疫耐受的环境中由外来抗原诱导产生,通过产生高水平的IL-10而发挥免疫抑制作用。而CD4 CD25 调节性T细胞(Tregs)可在胸腺中天然产生也可在外周被抗原诱导产生,通过细胞接触发挥抑制作用。现对Tr1细胞的表型、功能及其抑制作用机制等方面的研究进展进行综述。     

调节性 T 细胞发育的一个关键转录因子 Foxp3

调节性 T 细胞是目前免疫学领域研究的热点,对于维持机体免疫耐受和免疫应答稳态具有非常重要的作用 . 对其发育和功能机制的深入认识,不但有助于了解错综复杂的免疫系统理论,而且在自身免疫性疾病、肿瘤和艾滋病的治疗以及移植耐受的诱导等方面具有广泛的应用前景 . 最近的研究发现,转录因子 Foxp3 对于调节性 T 细胞的发育具有重要的作用,是调节性 T 细胞发育的一个关键转录因子 .     

老年COPD疾病进展与机体调节性T 细胞的关系分析

目的:探讨老年慢性阻塞性肺疾病(COPD)患者疾病进展与机体调节性T细胞(Treg)的关系。方法:选取我院收治的65例COPD患者(COPD组)以及同期在我院行体检的健康人群45例(正常对照组),将COPD患者分为急性期组41例及稳定期组24例,采用肺功能仪检测肺功能,采用酶联免疫吸附法检测血清γ-干扰素(IFN-γ)、白介素4(IL-4)、IL-17水平,采用流式细胞仪检测外周血CD4+CD25+Treg细胞比例。结果:与正常对照组比较,COPD患者的FEV1、FVC、PEF、FEV1/FVC、6MWT、血清IL-4水平、外周血CD4~+CD25~+Treg细胞比例均明显下降,血清IFN-γ、IL-17及Th1/Th2均显著升高。急性期COPD患者的CD4~+CD25~+Treg细胞比例较正常对照组显著升高,而正常对照组患者的CD4~+CD25~+Treg细胞比例较稳定组COPD患者显著升高,组间比较均有明显差异(P0.05)。结论:老年CODP患者体内存在免疫功能失调,调节性T细胞可能参与了老年COPD疾病的发病以及急性加重过程,导致患者出现肺功能改变。     

调节性T细胞及其调节机制

免疫系统中许多细胞相互作用以保护机体免受各种病原体造成的伤害,同时机体又发展了多种机制调控免疫系统以预防对自身抗原的免疫应答或对病原体的过度应答。除了抗原刺激免疫活性细胞激活和分化的内在稳态调节机制外,调节性T细胞所介导的外源性机制在免疫调节中发挥着举足轻重的作用。目前发现的调节性T细胞主要包括CD4+CD25+调节性T细胞、Tr1调节性T细胞、Th3调节性T细胞、CD8+调节性T细胞、NK T细胞、TCRγδ+T细胞、DN T细胞。本文介绍这些调节性T细胞的表型和作用机制的研究进展。     

诱导性调节性T细胞抑制移植排斥反应的作用研究

目的:通过体外诱导的方法将幼稚CD4+T细胞(na觙ve CD4+T cell)转化为调节性T细胞(RegulatoryT cells,Tregs),并验证其在小鼠异体皮片移植模型上对移植排斥反应的抑制作用。方法:分选na觙ve CD4+T细胞并在体外诱导其转化为Tregs,流式检测细胞确定其转化率。将诱导性Treg(induced Treg,iTreg)与效应T细胞(Effective T cells,Teffs)以不同比例共同培养检测其对T细胞增殖的抑制能力。建立C57bl/6到Balb/c小鼠的异体皮片移植模型,植皮术后将iTreg经由股静脉输注入受体(Balb/c小鼠)体内,观察皮片存活情况,绘制皮片存活曲线。同时于皮片移植术后11天对皮片进行病理切片,观察移植排斥反应状况。结果:体外诱导na觙ve CD4+T细胞转化为iTreg的比例约44%,在iTreg:Teff比例大于1:4时,iTreg具有明显地抑制Teff增殖的作用,且这种抑制作用具有剂量依赖性。植皮小鼠输注iTreg后皮片存活时间较对照组延长约2.4天,病理切片显示排斥反应减轻,但皮片在14天左右时仍被排斥。结论:体外诱导的iTreg能够在体外抑制Teff增殖,且能有效抑制小鼠异体皮片移植后排斥反应。     

CD4+CD25+调节性T细胞与肿瘤免疫

调节性T细胞是一类具有免疫抑制作用,调节自身T细胞功能的T细胞亚群,与维持免疫耐受、抑制自身免疫性疾病有关,CD4＋CD25＋调节性T细胞是其重要组成部分.该文介绍CD4＋CD25＋调节性T细胞在癌症患者免疫系统中的失调现象、机制和以其为靶点的免疫治疗方式.     

调节性T细胞研究进展

调节性T细胞（regulatory T cells,Treg）是具有调节功能的成熟T细胞亚群（Akira等．2002）,最初在自身免疫性疾病及肿瘤治疗的免疫学研究中被发现（Shevach等．2000）,因其具有抑制免疫反应的作用,一直被称作抑制性T细胞（Ts）。但随着细胞及分子生物学的飞速发展,Treg分子作用机制逐渐被阐明,其调节功能在机体免疫稳态维持、移植耐受、肿瘤免疫、过敏反应及微生物感染等方面均得到了证实。     

调节性T细胞的分化及其影响因素

调节性T细胞是近年发现的一种具有免疫抑制活性的CD4+T细胞亚群,它们可以在胸腺中被选择分化,也可以在外周淋巴组织内由转化生长因子-β等细胞因子诱导分化。本文就调节性T细胞分化过程的关键信号通路及影响因素进行综述。调控调节性T细胞的分化过程能够影响其在体内的数目,可通过对其数量的干预,为自身免疫性疾病、免疫监视、排斥反应及变态反应等相关疾病提供可能的治疗靶点。     

TCR Peptide Therapy in Human Autoimmune Diseases

Inflammatory Th1 cells reacting to tissue/myelin derived antigens likely contribute to the pathogenesis of diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. One regulatory mechanism that may be useful for treating autoimmune diseases involves an innate second set of Th2 cells specific for portions of the T cell receptor of clonally expanded pathogenic Th1 cells. These Th2 cells are programmed to respond to internally modified V region peptides from the T cell receptor (TCR) that are expressed on the Th1 cell surface in association with major histocompatibility molecules. Once the regulatory Th2 cells are specifically activated, they may inhibit inflammatory Th1 cells through a non-specific bystander mechanism. A variety of strategies have been used by us to identify candidate disease-associated TCR V genes present on pathogenic Th1 cells, including BV5S2, BV6S5, and BV13S1 in MS, BV3, BV14, and BV17 in RA, and BV3 and BV13S1 in psoriasis. TCR peptides corresponding to the mid region of these BV genes were found to be consistently immunogenic in vivo when administered either i.d. in saline or i.m. in incomplete Freund's adjuvant (IFA). In MS patients, repeated injection of low doses of peptides (100-300 g) significantly boosted the number of TCR-reactive Th2 cells. These activated cells secreted cytokines, including IL-10, that are known to inhibit inflammatory Th1 cells. Cytokine release could also be induced in TCR-reactive Th2 cells by direct cell-cell contact with Th1 cells expressing the target V gene. These findings indicate the potential of regulatory Th2 cells to inhibit not only the target Th1 cells, but also bystander Th1 cells expressing different V genes specific for other autoantigens. TCR peptide vaccines have been used in our studies to treat a total of 171 MS patients (6 trials), 484 RA patients (7 trials), and 177 psoriasis patients (2 trials). Based on this experience in 824 patients with autoimmune diseases, TCR peptide vaccination is safe and well tolerated, and can produce significant clinical improvement in a subset of patients that respond to immunization. TCR peptide vaccination represents a promising approach that is well-suited for treating complex autoimmune diseases.     

CD4+CD25+调节性T细胞

调节性T细胞(regulatory T cells,Treg)是机体维持自身耐受的重要组成部分。CD4^ CD25^ Treg细胞来源于胸腺,其主要功能是抑制自身反应性T细胞,并且其作用是通过直接的Treg-T效应细胞之间的相互接触方式来实现的。CD4^ CD25^ Treg细胞可分泌多种抑制性细胞因子,但与其抑制功能关系并不明确,目前有证据表明GITR和Foxp3与CD4^ CD25^ Treg细胞的抑制功能有关,并且Foxp3已作为CD4^ CD25^ Treg细胞的特异性标志。通过IL-10、TGF-β等抑制性细胞因子、imDC以及转基因技术可以产生具有免疫抑制功能的调节性T细胞。调节性T细胞在免疫相关性疾病、肿瘤免疫和抗感染免疫等方面具有重要意义。     

Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cells

Human tumor specific cytotoxic T lymphocytes (CTL) were expanded on formalin-fixed autologous target tumor cells derived from glioblastoma multiforme. Growth response of the CTL restimulated with the fixed target cells was larger than those with live target cells. The results suggest that formalin-fixed tumor cells will be stable sources of tumor antigen for efficient autologous CTL expansion and be useful for adoptive immunotherapy of tumors. This revised version was published online in August 2006 with corrections to the Cover Date.     

Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells

Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients achieving early complete remissions ultimately relapse. Immunosuppressive ligands are expressed on tumor and supportive cells in the tumor microenvironment (TME). When activated, T cells express associated “checkpoint” receptors. Binding of co-inhibitory ligands and receptors may directly contribute to T-cell functional exhaustion. It is not known whether all T cells engineered to express chimeric antigen receptors (CARs) are subject to checkpoint-mediated regulation. It is also unknown whether distinct CAR signaling moieties modulate T-cell responsiveness to these inhibitory pathways. We have, therefore, directly compared functional co-inhibition in engineered T cells identically targeted to the tumor-associated antigen CD123, but distinct in their mode of T-cell activation: via the endogenous T-cell receptor (ENG), or downstream of CD28 or 41BB-containing CARs. In all cases, we have observed antigen-independent T-cell activation associated with upregulation of the co-inhibitory receptors programmed cell death protein 1 (PD-1, CD279), Tim-3 and Lag-3. Notably, CD28.CAR T cells were uniquely susceptible to PD-1/PD-L1 mediated checkpoint inhibition. Together, our data indicate that PD-1/PD-L1 checkpoint blocking agents may be considered clinically when CD28.CAR T cells do not perform optimally in human trials.     

Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation

Background

Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity.

综述与专论：结直肠癌的免疫治疗

改善结直肠癌（colorectal cancer,CRC）患者的预后具有重要的临床和社会意义。免疫治疗是一种新兴的肿瘤治疗方式,免疫检查点抑制剂已在DNA错配修复缺陷/高微卫星不稳定型CRC的治疗中实现了良好的临床转化,占绝大多数的DNA错配修复完整/微卫星稳定型CRC患者却很难在该疗法中获益。免疫疫苗、过继性细胞疗法等其他免疫疗法的临床研究也在积极推进中,虽然展示了一定的良性结果,但仍面临着难以有效突破肿瘤抑制性微环境等诸多问题而未能获得实质性进展。本文以各种免疫治疗方案相关的临床试验为主线进行综述,以期明确CRC免疫治疗的进展,为更优治疗方案的探索提供依据。     

MTOR signaling is essential for the development of thymic epithelial cells and the induction of central immune tolerance

Thymic epithelial cells (TECs) are critical for the establishment and maintenance of appropriate microenvironment for the positive and negative selection of thymocytes and the induction of central immune tolerance. Yet, little about the molecular regulatory network on TEC development and function is understood. Here, we demonstrate that MTOR (mechanistic target of rapamycin [serine/threonine kinase]) is essential for proper development and functional maturation of TECs. Pharmacological inhibition of MTOR activity by rapamycin (RPM) causes severe thymic atrophy and reduction of TECs. TEC-specific deletion of Mtor causes the severe reduction of mTECs, the blockage of thymocyte differentiation and output, the reduced generation of thymic regulatory T (Treg) cells and the impaired expression of tissue-restricted antigens (TRAs) including Fabp2, Ins1, Tff3 and Chrna1 molecules. Importantly, specific deletion of Mtor in TECs causes autoimmune diseases characterized by enhanced tissue immune cell infiltration and the presence of autoreactive antibodies. Mechanistically, Mtor deletion causes overdegradation of CTNNB1/Beta-Catenin due to excessive autophagy and the attenuation of WNT (wingless-type MMTV integration site family) signaling in TECs. Selective inhibition of autophagy significantly rescued the poor mTEC development caused by Mtor deficiency. Altogether, MTOR is essential for TEC development and maturation by regulating proliferation and WNT signaling activity through autophagy. The present study also implies that long-term usage of RPM might increase the risk of autoimmunity by impairing TEC maturation and function.